{"disease":{"id":"treatment-of-acute-myeloid-leukemia-aml","name":"treatment of acute myeloid leukemia aml"},"drugs":{"marketed":[{"drug_id":"part-c-met097","indication_name":"Treatment of Acute Myeloid Leukemia (AML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05577611","title":"An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"Zhongnan Hospital","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}